Replies to post #214436 on Biotech Values

[DewDiligence]

GLMD had $19.0M of cash at 12/31/17—thanks to ATM sales during December (at relatively high prices):

https://www.sec.gov/Archives/edgar/data/1595353/000114420418000046/tv482405_ex99-1.htm

Galmed Pharmaceuticals…today announced it raised approximately $11.6 million in gross proceeds during December 2017 under the Company’s at-the-market (“ATM”) programs. The Company issued 1,368,667 ordinary shares under its former and existing ATM programs during December 2017 at an average sale price of $8.45 per share.

…Based on preliminary unaudited financial information, as of December 31, 2017, Galmed has cash and cash equivalents and marketable securities of approximately $19.0 million.

This is more than enough cash to carry GLMD to the data readout of the phase-2/3 ARREST trial in NASH, expected in 1Q18.